Search details
1.
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.
Muscle Nerve
; 66(1): 50-62, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35428982
2.
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with ß-thalassemia.
Blood
; 133(12): 1279-1289, 2019 03 21.
Article
in English
| MEDLINE | ID: mdl-30617198
3.
Sotatercept, a novel transforming growth factor ß ligand trap, improves anemia in ß-thalassemia: a phase II, open-label, dose-finding study.
Haematologica
; 104(3): 477-484, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30337358
4.
Locally acting ACE-083 increases muscle volume in healthy volunteers.
Muscle Nerve
; 57(6): 921-926, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29486514
5.
Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Lancet Oncol
; 18(10): 1338-1347, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28870615
6.
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.
Muscle Nerve
; 55(4): 458-464, 2017 04.
Article
in English
| MEDLINE | ID: mdl-27462804
7.
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Cancer
; 122(23): 3641-3649, 2016 Dec 01.
Article
in English
| MEDLINE | ID: mdl-27648727
8.
A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers.
Am J Hematol
; 89(7): 766-70, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24715706
9.
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.
Muscle Nerve
; 47(3): 416-23, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23169607
10.
Long-term safety and erythroid response with luspatercept treatment in patients with ß-thalassemia.
Ther Adv Hematol
; 13: 20406207221134404, 2022.
Article
in English
| MEDLINE | ID: mdl-36505885
11.
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
J Clin Oncol
; 40(33): 3800-3807, 2022 11 20.
Article
in English
| MEDLINE | ID: mdl-35998303
12.
Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease.
Neurology
; 2022 May 11.
Article
in English
| MEDLINE | ID: mdl-35545446
13.
Abnormal growth in noonan syndrome: genetic and endocrine features and optimal treatment.
Horm Res
; 70(3): 129-36, 2008.
Article
in English
| MEDLINE | ID: mdl-18663312
14.
Relationship between insulin sensitivity and IGF-I sensitivity in low birth weight prepubertal children.
Horm Res
; 70(2): 73-8, 2008.
Article
in English
| MEDLINE | ID: mdl-18547952
15.
Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
Lancet Haematol
; 5(2): e63-e72, 2018 Feb.
Article
in English
| MEDLINE | ID: mdl-29331635
16.
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma.
Clin Cancer Res
; 23(14): 3557-3565, 2017 Jul 15.
Article
in English
| MEDLINE | ID: mdl-28031424
17.
Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature.
J Clin Endocrinol Metab
; 90(9): 5247-53, 2005 Sep.
Article
in English
| MEDLINE | ID: mdl-15998780
18.
Efficacy of a long-acting growth hormone (GH) preparation in patients with adult GH deficiency.
J Clin Endocrinol Metab
; 90(12): 6431-40, 2005 Dec.
Article
in English
| MEDLINE | ID: mdl-16159930
19.
Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study.
J Clin Endocrinol Metab
; 88(11): 5273-80, 2003 Nov.
Article
in English
| MEDLINE | ID: mdl-14602761
20.
A long-acting human growth hormone (Nutropin Depot): efficacy and safety following two years of treatment in children with growth hormone deficiency.
J Pediatr Endocrinol Metab
; 15 Suppl 2: 715-22, 2002 May.
Article
in English
| MEDLINE | ID: mdl-12092685